Radiopharmaceuticals and Methods of Radiolabeling

  • Gopal B. Saha

Abstract

A radiopharmaceutical is a radioactive compound used for the diagnosis and therapeutic treatment of human diseases. In nuclear medicine nearly 95% of the radiopharmaceuticals are used for diagnostic purposes, while the rest are used for therapeutic treatment. Radiopharmaceuticals usually have no pharmacologic effect, because in most cases they are used in tracer quantities. In these cases, they do not show any dose-response relationship and thus differ from conventional drugs. Because they are administered to humans, they should be sterile and pyrogen free, and they should undergo all quality control measures required of a conventional drug. A radiopharmaceutical may be a radioactive element such as 133Xe, or a labeled compound such as 131I-iodinated proteins and 99mTc-labeled compounds.

Keywords

Rose Bengal Label Compound Stannous Chloride Label Yield Bifunctional Chelate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Billinghurst MW, Rempel S, Westendorf BA. Radiation decomposition of technetium-99m radiopharmaceuticals. J Nucl Med. 1979; 20 : 138.PubMedGoogle Scholar
  2. Clark MJ, Podbielski L. Medical diagnostic imaging with complexes of Tc-99m. Coord Chem Rev. 1987; 78: 253.CrossRefGoogle Scholar
  3. Cobble JW. Technetium. In: Kolthoff IM, Elving PJ, eds. Treatise on Analytical Chemistry, Part II. New York: Wiley/Interscience; 1964; II : 407.Google Scholar
  4. Deutsch E, Nicolini M, Wagner HN, Jr, eds. Technetium in Chemistry and Nuclear Medicine. Verona: Cortina International; 1983.Google Scholar
  5. Dewanjee MK. The chemistry of 99mTc-labeled radiopharmaceuticals. Semin Nucl Med. 1990; XX : 5.Google Scholar
  6. Dewanjee MK, Rao SA. Principles of radioiodination and iodine-labeled tracers in biomedical investigation. In: Rayudu GVS, ed. Radiotracers for Medical Applications. Boca Raton, Fla: CRS Press; 1983; 2: 1.Google Scholar
  7. Eckelman WC, Coursey BM, eds. Technetium-99m. Int J Appl Rad Isot. 1982; 33 : 843.Google Scholar
  8. Eckelman WC, Levenson SM. Radiopharmaceuticals labelled with technetium. In: Welch MJ, ed. Radiopharmaceuticals and Other Compounds Labelled with Short-lived Radionuclides. New York: Pergamon Press; 1977 : 67.Google Scholar
  9. Eckelman WC, Levenson SM, 1978. Radiopharmaceutical chemistry of technetium and iodine. In: Rocha AFG, Harbert JC, eds. Textbook of Nuclear Medicine: Basic Science. Philadelphia: Lea & Febiger; 1978 : 192Google Scholar
  10. Jones AG, Davison A. The Chemistry of Tc(I), II, III, IV. Int J Appl Rad Isot. 1982; 33 : 867.CrossRefGoogle Scholar
  11. Jones AG, Davison A. The relevance of basic technetium chemistry to nuclear medicine. J Nucl Med. 1982; 23 : 1041.PubMedGoogle Scholar
  12. Kotegov KV, Pavlov ON, Shvedov VP. Technetium. In: Advances in Inorganic Chemistry and Radiochemistry. New York: Academic Press; 1968:2.Google Scholar
  13. Lathrop KA. Preparation and control of 99mTc radiopharmaceuticals. In: Radiopharmaceuticals from Generator-Produced Radionuclides. Vienna: IAEA; 1971:39.Google Scholar
  14. Lathrop KA, Harper PV, Rich BH, et al. Rapid incorporation of short-lived cyclotron produced radionuclides into radiopharrnaceuticals. In: Radiopharmaceuticals and Labeled Compounds. Vienna: IAEA; 1973 : 471.Google Scholar
  15. Mani RS, Narasimhan DVS. Development of kits for short-lived generatorproduced radioisotopes. In: Radiopharmaceuticals and Labelled Compounds. Vienna: IAEA; 1973; 1 : 135 .Google Scholar
  16. McFarlane AS. Efficient trace-labeling of proteins with iodine. Nature. 1958; 182:53.PubMedCrossRefGoogle Scholar
  17. Nicolini M, Bandoli G, Mazzi U, eds. Technetium in chemistry and nuclear medicine. Verona: Cortina International; 1986.Google Scholar
  18. Richards P, Steigman J. Chemistry of technetium as applied to radiopharmaceuticals. In: Subramanian G, Rhodes BA, Cooper JF, Sodd VJ, eds. Radiopharmaceuticals. New York: Society of Nuclear Medicine; 1975 : 23.Google Scholar
  19. Srivastava SC, Meinken G, Smith TD, Richards P. Problems associated with stannous 99mTc-radiopharmaceutical, In: Welch MJ, ed. Radiopharmaceulicals and Other Compounds Labelled with Short-Lived Radionuclides. New York: Pergamon Press; 1977 : 83.Google Scholar
  20. Wilbur DS, Hadley SW, Hylarides MD, et al. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med. 1989; 30:216.PubMedGoogle Scholar
  21. Yalow RS, Berson SA. Labeling of proteins—Problems and practices. NY Acad Sci. 1966; 28 :1033.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Gopal B. Saha
    • 1
  1. 1.Department of Nuclear MedicineThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations